ArticleJACC. Case reports2025
Ranolazine-Induced Type 1 Brugada Pattern.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBrugada syndrome (BrS) is a rare inherited arrhythmia disease carrying a variable risk of sudden cardiac death. Diagnosis requires the type 1 Brugada electrocardiographic pattern, which can either be spontaneous or induced by sodium channel-blocking drugs. Ranolazine is an antianginal drug acting on the late sodium current with emerging antiarrhythmic properties; no information is available on the safety of ranolazine use in patients with BrS. CASE SUMMARY: We present the case of a 48-year-old man with recent history of ST-elevation myocardial infarction and residual microvascular angina who developed a type 1 Brugada pattern after starting therapy with ranolazine. DISCUSSION: Ranolazine has been demonstrated to be effective as an antiarrhythmic drug in several conditions in which other sodium-channel blockers are currently employed (eg, atrial fibrillation and type 3 long QT syndrome). Given the mechanism of action, it is plausible to hypothesize a potential role of ranolazine in unmasking the type 1 Brugada pattern. TAKE-HOME MESSAGES: Evidence of the safety of ranolazine in patients with BrS is lacking. A possible connection between ranolazine assumption and the unmasking of a type 1 Brugada pattern may question its use in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.